Monteleukast Versus Inhaled Mometasone for Treatment of Otitis Media With Effusion in Children

NCT ID: NCT02541760

Last Updated: 2015-09-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

143 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-04-30

Study Completion Date

2015-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Otitis media is one of the most common infections among children and is a complication in about 30% of common colds. The most common complication of acute otitis media is otitis media with effusion. Some studies have reported the effects of montelukast and mometasone nasal spray in treatment of otitis media with effusion. However, current information is inadequate in this issue. The aim of this study was to compare the effectiveness of montelukast and mometasone nasal spray in treatment of otitis media with effusion in children attending Koodakan hospital in Bandar Abbas, Iran.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Otitis Media With Effiusion

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Montelukast

4 ml monteleukast daily for one month

Group Type EXPERIMENTAL

Monteleukast

Intervention Type DRUG

4 ml monteleukast daily for one month

Mometasone

Inhaled mometasone 1 puff in each side of nose for one month

Group Type ACTIVE_COMPARATOR

Mometasone

Intervention Type DRUG

Inhaled mometasone 1 puff in each side of nose for one month

Control

No intervention

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monteleukast

4 ml monteleukast daily for one month

Intervention Type DRUG

Mometasone

Inhaled mometasone 1 puff in each side of nose for one month

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* • Children who were between 2 to 6 years old

* Definite diagnosis of OME with symptoms and examination

Exclusion Criteria

* • Currently were using corticosteroids or prophylactic monteleukast

* Chronic pulmonary or cardiac diseases or immune deficiency
* Allergic rhinitis
* Hypersensitivity to monteleukast or corticosteroids
* Avoidance of parents to fill the written informed consent
Minimum Eligible Age

2 Years

Maximum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hormozgan University of Medical Sciences

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Hamidreza Mahboobi

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hamidreza Mahboobi, M.D

Role: PRINCIPAL_INVESTIGATOR

Hormozgan University of Medical Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hormozgan University of Medical Sciences

Bandar Abbas, Hormozgan, Iran

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Iran

References

Explore related publications, articles, or registry entries linked to this study.

Mulvaney CA, Galbraith K, Webster KE, Rana M, Connolly R, Tudor-Green B, Marom T, Daniel M, Venekamp RP, Schilder AG, MacKeith S. Topical and oral steroids for otitis media with effusion (OME) in children. Cochrane Database Syst Rev. 2023 Dec 13;12(12):CD015255. doi: 10.1002/14651858.CD015255.pub2.

Reference Type DERIVED
PMID: 38088821 (View on PubMed)

Rahmati MB, Safdarian F, Shiroui B, Zare S, Sadeghi N. Montelukast versus inhaled mometasone for treatment of otitis media with effusion in children: A randomized controlled trial. Electron Physician. 2017 Jul 25;9(7):4890-4894. doi: 10.19082/4890. eCollection 2017 Jul.

Reference Type DERIVED
PMID: 28894551 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

163

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Wheeze and Intermittent Treatment
NCT01142505 COMPLETED PHASE3
Montelukast With Status Asthmaticus, Ages 6-18
NCT00494572 UNKNOWN PHASE2/PHASE3
Montelukast for Early Life Wheezing
NCT00115297 COMPLETED PHASE2/PHASE3